These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27100995)

  • 1. Rivaroxaban in Chronic Hemodialysis Patients.
    Muster H; Alcorn H
    Am J Nephrol; 2016; 43(4):227-8. PubMed ID: 27100995
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Editorial].
    Özdemir M
    Turk Kardiyol Dern Ars; 2017 Sep; 45(Suppl 4):III. PubMed ID: 28947722
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
    Saleem A
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):S129-S130. PubMed ID: 28969751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of rivaroxaban in patients attending a hematology unit in clinical practice.
    Sebastián OG; Fernández MI; Fernández RM; Bernal LP
    Future Cardiol; 2019 Sep; 15(5):347-353. PubMed ID: 31468995
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
    Lindner SM; Fordyce CB; Hellkamp AS; Lokhnygina Y; Piccini JP; Breithardt G; Mahaffey KW; Singer DE; Hacke W; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Becker RC; Fox KA; Patel MR;
    Circulation; 2017 Mar; 135(10):1001-1003. PubMed ID: 28264892
    [No Abstract]   [Full Text] [Related]  

  • 12. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease.
    Rapista N; Sarkar S; Chaudhary R
    J Thromb Thrombolysis; 2020 Nov; 50(4):982-983. PubMed ID: 32495012
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivaroxaban for thromboprophylaxis in a patient receiving electroconvulsive therapy.
    Shuman M; Hieber R; Moss L; Patel D
    J ECT; 2015 Mar; 31(1):e19-20. PubMed ID: 25587812
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban twice daily for lysis of left atrial appendage thrombus: a potential new therapeutic option.
    Piotrowski R; Zaborska B; Baran J; Sikora-Frąc M; Kułakowski P
    Pol Arch Med Wewn; 2016 Jun; 126(6):430-1. PubMed ID: 27305139
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain.
    Escobar Cervantes C
    Future Cardiol; 2018 May; 14(3s):1-2. PubMed ID: 29848088
    [No Abstract]   [Full Text] [Related]  

  • 18. Rivaroxaban: can we trust the evidence?
    Cohen D
    BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
    Langenbruch L; Meuth SG; Wiendl H; Mesters R; Möddel G
    Seizure; 2020 Aug; 80():46-47. PubMed ID: 32521502
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation].
    Cui J; Du X; Wu JH; Jia CQ; Li X; Ning M; Lyu J; Yang Y; Liu XH; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Aug; 46(8):606-610. PubMed ID: 30139010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.